Volume 32, Issue 215 (12-2022)
J Mazandaran Univ Med Sci 2022, 32(215): 163-168 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Alikhani A, Nekoukar Z, Moghimi M, Rezapour M, Boskabadi S J, Shabani A M et al . Efficacy of Tocilizumab in Patients with COVID-19. J Mazandaran Univ Med Sci 2022; 32 (215) :163-168
URL: http://jmums.mazums.ac.ir/article-1-18510-en.html
URL: http://jmums.mazums.ac.ir/article-1-18510-en.html
Ahmad Alikhani 
, Zahra Nekoukar , Minoo Moghimi , Maysam Rezapour , Seyyed Javad Boskabadi , Amir Mohammad Shabani , Hamideh Abbaspour Kasgari
, Zahra Nekoukar , Minoo Moghimi , Maysam Rezapour , Seyyed Javad Boskabadi , Amir Mohammad Shabani , Hamideh Abbaspour Kasgari
Abstract: (1300 Views)
Background and purpose: Tocilizumab (TCZ), a monoclonal antibody against interleukin-6 (IL-6) receptor, is emerged as an alternative treatment for COVID-19 patients with a risk of cytokine storms. This study aimed at investigating the efficacy of TCZ in patients with COVID-19.
Materials and methods: In a retrospective observational study, we examined the demographic and clinical characteristics of patients with COVID-19 and also the outcomes of TCZ therapy (Actemra® and Temziva®) in Qaemshahr Razi Hospital.
Results: Out of 56 cases, 32 (57.1%) were women and the median age of the patients was 57.5 years. Among the patients, 19 (33.9%) were admitted to ICU where seven (12.7%) were intubated and eight (14.3%) patients deceased. Before TCZ therapy, mean oxygen saturation level was 90.1% which elevated to 93.8% after receiving TCZ (P=0.001). In this study, Temziva® was associated with lower mortality rate compared with Actemra® (P=0.004).
Conclusion: TCZ therapy in patients with COVID-19 could improve oxygen saturation level and Temziva® results in lower mortality rate. However, further studies with larger sample size are required to confirm these results.
Materials and methods: In a retrospective observational study, we examined the demographic and clinical characteristics of patients with COVID-19 and also the outcomes of TCZ therapy (Actemra® and Temziva®) in Qaemshahr Razi Hospital.
Results: Out of 56 cases, 32 (57.1%) were women and the median age of the patients was 57.5 years. Among the patients, 19 (33.9%) were admitted to ICU where seven (12.7%) were intubated and eight (14.3%) patients deceased. Before TCZ therapy, mean oxygen saturation level was 90.1% which elevated to 93.8% after receiving TCZ (P=0.001). In this study, Temziva® was associated with lower mortality rate compared with Actemra® (P=0.004).
Conclusion: TCZ therapy in patients with COVID-19 could improve oxygen saturation level and Temziva® results in lower mortality rate. However, further studies with larger sample size are required to confirm these results.
Type of Study: Brief Report |
Subject:
infection
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Articles Copyright © The Author(s). Owned by Mazandaran University of Medical Sciences.
Contact Us
Address: Journal Office, Building No. 2, Mazandaran University of Medical Sciences, Moallem Square, Sari.Tel: +98 (011)34484874 Postal code: 48175-866 E-Mail: jmums@mazums.ac.ir Telefax: +98 (011)33262679
